LEADER 04085nam  22005655  450 
001 9910350320203321
005 20200704221637.0
010   $a981-13-8906-3
024 7 $a10.1007/978-981-13-8906-1
035   $a(CKB)4100000009836957
035   $a(MiAaPQ)EBC5968658
035   $a(DE-He213)978-981-13-8906-1
035   $a(EXLCZ)994100000009836957
100   $a20191024d2019      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug Discovery in Japan $eInvestigating the Sources of Innovation /$fedited by Sadao Nagaoka
205   $a1st ed. 2019.
210  1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2019.
215   $a1 online resource (xv, 333 pages) $cillustrations
300   $aIncludes index.
311   $a981-13-8905-5 
327   $aForeword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
330   $aThis book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.
606   $aEconomic policy
606   $aManagement
606   $aIndustrial management
606   $aJapan?History
606   $aR & D/Technology Policy$3https://scigraph.springernature.com/ontologies/product-market-codes/W43000
606   $aInnovation/Technology Management$3https://scigraph.springernature.com/ontologies/product-market-codes/518000
606   $aHistory of Japan$3https://scigraph.springernature.com/ontologies/product-market-codes/715020
615  0$aEconomic policy.
615  0$aManagement.
615  0$aIndustrial management.
615  0$aJapan?History.
615 14$aR & D/Technology Policy.
615 24$aInnovation/Technology Management.
615 24$aHistory of Japan.
676   $a615.190941
702   $aNagaoka$b Sadao$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910350320203321
996   $aDrug Discovery in Japan$91939025
997   $aUNINA